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Human immunodeﬁciency virus type 1 (HIV-1) emerged in the
human population shortly after the turn of the 19th century. Distribu-
tion of HIV-1 across the globe over the past 30–35 years can be traced
to founder events with primordial HIV strains from sub-Saharan Africa
(Sharp and Hahn, 2011; Arien et al., 2007; Arien et al., 2007; Tebit and
Arts, 2011), a regionwhich is still the HIV epicenter with 30million his-
toric and 28 million current infections (Sharp and Hahn, 2011; Arien et
al., 2007; Tebit and Arts, 2011). Even in light of the burden of HIV in Af-
rica, our knowledge of HIV-1 disease is still largely limited to subtype B
HIV-1, a strain responsible for 3million infections in North America and
Europe as compared to the 33 million that are infected with HIV-1d Immunology, Western
ond St., London, ON N6A
is an open access article undersubtypes A, C, D, and circulating and unique recombinant forms (CRFs
and URFs, Fig. 1). Over the past 25 years (1990 to 2015), the expansion
of 27.2 million new infections is largely due to the predominant spread
of HIV-1 subtype C (accounting for 14.5 million new infections) over all
other HIV-1 subtypes and recombinant forms. As documented in many
reports, different HIV subtypes pre-dated the introduction of subtype C
in southern Africa, South Asia, and Brazil but the rapid expansion of
these epidemics in the past 25 years appears to coincide with the
founding of HIV-1 subtype C in the heterosexual population.
The extreme genetic diversity between HIV-1 subtypes has pheno-
typic consequences in vitro including differential HIV-1 mRNA tran-
scriptional control (Montano et al., 2000; van et al., 2004), protease
activity (Velazquez-Campoy et al., 2001), integration site selection
(Demeulemeester et al., 2014), MHC class I downregulation (Mann et
al., 2014), and entry efﬁciency (Marozsan et al., 2005). Overall, subtype
C HIV-1 isolates have lower replicative ﬁtness in tissue culture relative
to HIV-1 isolates of any other subtype (Abraha et al., 2009; Ball et al.,
2003; Arien et al., 2005). Relevance of these in vitro HIV studies to viru-
lence would require comprehensive analyses on the natural history ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Thenumber of people livingwithHIV-1 between1980 and 2015 in the fourUNAIDSRegionswith the greatest number of infections aswell as globally. Thedistribution of subtypes in
1990 and 2015 are shown in the inset pie graphs, scaledby thenumber of infections. Relative amounts of subtype C infectionsper UNAIDSRegion are reported on the pie graphs and via red
shading. Data compiled from theWorld Health Organization, UNAIDS and published literature.
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guide treatment and prevention strategies in the majority of people
currently living with HIV-1. Longitudinal and cross-sectional studies
in sub-Saharan Africa have suggested different disease courses and
treatment outcomes in individuals infected with subtype A, B, C, D
and URFs/CRFs (Amornkul et al., 2013; Rainwater et al., 2005; Baeten
et al., 2007; Kaleebu et al., 2002; Palm et al., 2014; Kanki et al., 1999;
Kiwanuka et al., 2009), the most signiﬁcant being the faster disease
progression and higher rates of treatment failures in subtype D versus
subtype A infections (Baeten et al., 2007; Kaleebu et al., 2002; Kyeyune
et al., 2013).
From 1999 to 2003, over 4400 HIV-negative women in Uganda and
Zimbabwe were enrolled in the Hormonal Contraception and the Risk
of HIV Acquisition (HC-HIV) Study (Morrison et al., 2007), during
which 303 womenwere identiﬁed with incident HIV infection and par-
ticipated in the Hormonal Contraception and HIV-1 Genital Shedding
and Disease Progression among Women with Primary HIV Infection
(GS) Study (Morrison et al., 2010; Morrison et al., 2011; Lemonovich
et al., 2015). The 76 subtype A, 177 subtype C, 31 subtype D and two
URF HIV infectedwomen (286 of 303 women)were followed for an av-
erage of 5 years, currently the largest natural history cohort of non-sub-
type B infections. ConsistentwithWHOrecommendations at the time of
the study, treatment was provided when HIV-infected participants
reached CD4 cell counts below 200/ml on two consecutive tests or
were diagnosed with stage IV or advanced III disease (WHO Classiﬁca-
tion). It should be noted that anti-retroviral therapy (ART) was not yet
routinely available in these countries at the start of this study period.
This study was designed to monitor immune and viral parameters and
to compare these biomarkers of disease progression to country of origin,contraceptive use, infecting subtype, and phenotypic properties of the
virus.
2. Materials and Methods
2.1. Participants and Clinical Tests
A complete description of the Ugandan and Zimbabwean partici-
pants is previously described (Morrison et al., 2011; Lemonovich et al.,
2015). Women who became HIV infected while participating in the
Hormonal Contraception and Risk of HIV Acquisition Study in Uganda
and Zimbabwe (Morrison et al., 2007) were enrolled upon primary
HIV-1 infection into a subsequent study, the Hormonal Contraception
and HIV-1 Genital Shedding and Disease Progression among Women
with Primary HIV Infection (GS) Study (Morrison et al., 2010;
Morrison et al., 2011; Lemonovich et al., 2015). Ethical approval was ob-
tained from the Institutional Review boards (IRBs) from the Joint Clini-
cal Research Centre and UNST in Uganda, fromUniversity of Zimbabwe,
from the University Hospitals of Cleveland, and recently, fromWestern
University. Protocol numbers and documentation of these approvals/re-
newals are available upon request. 71% (N= 203 of 286) were enrolled
within 18 weeks of the infection date. Blood and cervical samples were
collected every month for the ﬁrst six months, then every three months
for the ﬁrst two years, and then every six months up to 9.5 years.
Women who had CD4 lymphocyte counts of 200 cells/ml and/or who
developed severe symptoms of HIV infection (WHO clinical stage IV or
advanced stage III disease) were offered combination ART (cART) and
trimethoprim-sulfamethoxazole (for prophylaxis against bacterial in-
fections and Pneumocystis jeroveci pneumonia). In addition, information
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formation, sexual behavior, sexually transmitted and reproductive
tract infections, opportunistic infections, and diet.
Following primary infection, 112 Uganda and 174 Zimbabwean
women were followed for an average 1826 and 1899 days (respective-
ly) for a maximum of 3453 days (9.5 years) (Suppl. Fig.1a). Antiretrovi-
ral treatment was initiated in 23% of the women in both countries but
100 days sooner on average in the Ugandan versus Zimbabwean
women (1458 versus 1558 days) (Suppl. Fig.1b). As described
(Morrison et al., 2010), cervical and plasma viral loadswere determined
with the Roche Amplicor HIV-1Monitor Test, version 1.5 using cryopre-
served samples from every three month visits. CD4 T-lymphocyte
counts were determined by standard ﬂow cytometry using FACSCalibur
(Becton Dickinson, Sparks, MD, USA).
2.2. Models to Determine Viral Load Increases and CD4 Cell Declines
A marginal model with the generalized estimating equation (GEE)
approach including autoregressive error structures (accounting for re-
peated measurements on the same individual) was used to determine
the plasma viral load changes and compare rates of CD4 cell decline
(Morrison et al., 2010). Multivariable analyses included demographic,
sexual, contraceptive andmedical history data and underwent stepwise
model simpliﬁcation with a signiﬁcance threshold of p ≤ 0.05. All analy-
ses used Stata Version 14 (StataCorp LP, College Station, TX).
2.3. DNA Sequencing and Subtyping
DNAwas extracted frompatient PBMC samples obtained at the sero-
conversion visit and every 3months post HIV infection. Primers speciﬁc
to the protease (PR) and polymerase regions of reverse transcriptase
(RT), and C2-V3 envelope (env) coding regions were used to PCR 300,
800, and 450 nt regions as described (Abraha et al., 2009) in a Virology
Quality Assurance (VQA) certiﬁed laboratory in Kampala, Uganda
(Morrison et al., 2010). The HIV-1 sequences were edited using BioEdit
v7.0.4 and PR-RT coding regions were uploaded into the Stanford Uni-
versity HIV Drug resistance database (http://hivdb.stanford.edu) to ob-
tain drug resistance proﬁles. Phylogenetic alignments were performed
using maximum likelihood methods (MUSCLE (Edgar, 2004)) and
trees constructed using SEAVIEW 4 (Gouy et al., 2010) and FigTree 1.4
(http://tree.bio.ed.ac.uk/software/ﬁgtree/). Each participant PR, RT,
and env sequence was aligned to curated set of subtype A, B, C, D, G,
and CRFs HIV-1 reference sequences (hiv.lanl.gov).
2.4. Virus Cloning and Propagation
The entire gp120 coding region and the extracellular domain of gp41
(referred to as env DNA) was PCR ampliﬁed with the ENV REC primer
set from PBMC DNA derived from the seroconversion visit. This Env
PCR product was cloned into pREC_nﬂNL4–3Δenv by yeast recombina-
tion/gap repair as described previously. pREC_nﬂ (containing the pa-
tient derived env gene) was transfected to produce virus-like particles
for entry and cell fusion assays. Co-transfections with pCMV_cplt in
293T cells produces replication-competent virus for replicative ﬁtness
(Dudley et al., 2009).
2.5. Replicative Fitness
47 primary HIV-1 isolates of subtypes A (Arien et al., 2005), C
(Dudley et al., 2009), and D (Mann et al., 2014) derived from patients
from around the world were tittered on PHA-activated, IL2-treated
PBMCs of HIV-negative donors using the standard Reed-Munch TCID50
determination (Reed and Muench, 1938) then competed against 25
subtype B primary HIV-1 in the same PBMCs. The primary isolates of
HIV-1 subtype A, B, C and D were all obtained from chronic infection,
many are part of the WHO collection, whereas others were isolatedfrom our laboratory in Uganda. A complete summary of all the viruses
is available upon request. All of the viruses have been previously
screened for co-receptor usage. Any CXCR4-using or dual tropic viruses
were excluded from this analysis.We also competed chimeric env virus-
es derived from the acute/early infection samples of 5 subtype A, 3 sub-
type D, and 5 subtype C infections of this cohort against two reference
chimeric env viruses derived from subtype B HIV-1 samples, B-Q0 and
B-K44. The reference B-Q0 and B-K44 were derived from untreated pa-
tient Q at early infection (month 0) and from untreated patient K at 44
months post infection (Troyer et al., 2005; King et al., 2013). The chime-
ric env viruses had the env gene from the AHI sample or the chronic ref-
erence sample cloned into the HIV-1 NL4-3 backbone using our yeast-
based cloning technique (Dudley et al., 2009). The reference chimeric
env virus with chronic subtype B HIV-1 has been employed in multiple
published and in press studies and serves as a reference competitor
virus to standardize relative ﬁtness. The relative production of two vi-
ruses in each competition was measured by a radiolabeled heterodu-
plex tracking assays (HTA) or using next generation sequencing (NGS)
(Abraha et al., 2009; Ball et al., 2003; Arien et al., 2005; Rubio et al.,
2014). It is important to note that same relative ﬁtness values (b5% var-
iance) was obtained using the HTA and NGS, a ﬁnding that will be re-
ported in submitted methods paper. Assay sensitivity is 100-fold
differences in replicative ﬁtness expressed as percentages.
2.6. Cell-to-Cell Infections
Veritrop involved the transfection (Fugene 6, Promega) of the
pRECnﬂ constructs containing patient envs into 6.5 × 104 HEK293T
cells (Weber et al., 2013) and cocultured with target U87 cells. Detailed
methods are published previously. Fully inhibitory concentrations of
Enfuvirtide (3 μM) were added at discrete time points (t = 4 to 7 h)
and luciferase production was quantiﬁedwith the Bright-Glo Luciferase
Assay System (Promega) to measure relative cell fusion. Drug treated
cells were compared to untreated controls to calculate percentmaximal
fusion. Time required to reach 50% maximal fusion by different env in
pREC-NFL constructs subtype were statistically compared using
ANOVA (STATA Version 14).
2.7. Virus Entry Into Host Cells
Cell-free viral entry utilized the pMM310 plasmid (NIH AIDS Repos-
itory, cat #11,444) to generate patient env viruses containing the HIV-1
accessory protein Vpr fused to E. coli β-lactamase (BlaM). Cells were
placed on a plate reader and virus entry was quantiﬁed every 15 min
by comparing changes in emission spectra (460 nm cleaved dye relative
to 530 nm uncleaved dye), then normalized relative to cell-free and
virus-free controls to determine time required to reach 75% maximal
viral entry (ANOVA).
3. Results
3.1. Monitoring Disease Progression in the Absence of Treatment
Newly infected women in Uganda (N = 112) and Zimbabwe (N =
174) were followed after acute/early HIV infection (AHI) for an average
of 5.1 years up to 9.5 years in the absence of combination antiretroviral
therapy (cART), initiated when CD4 cell counts dropped below 200/
mm3 (Suppl. Fig. 1). Complete sociodemographic, clinical blood chemis-
tries, and other clinical data has been reported (Morrison et al., 2010;
Morrison et al., 2011; Lemonovich et al., 2015; Lovvorn et al., 2010).
Lower CD4 cell levels were reported in Zimbabwean as compared to
Ugandan women (Lovvorn et al., 2010), both uninfected and in women
with AHI. Despite this difference between countries, declines in CD4 T-
cells was 2-fold slower in the Zimbabwean than in the Ugandanwomen
in the absence of treatment, translating to 2 to 5 years of longer asymp-
tomatic disease (Fig. 2a, Suppl. Fig. 2) (GEE model; P b 0.001). Virus
Fig. 2. CD4+ cell declines inHIV-1 infectedUgandan (n=112) and Zimbabweanwomen (n=174) during the natural course of disease. (a) Themean loss of CD4 cells permm3 perweek
of infection in Ugandan and Zimbabwean women and (c) in those women infectedwith subtypes A, C, and D. (b) The percentage of rapid progressors and slow progressors/controllers in
Ugandan and Zimbabweanwomen and (d) in thosewomen infectedwith subtypes A, C, andD. Rapid progressors are deﬁned asHIV-1 infectedwomenwith a drop to 200 CD4 cell counts/
mm3 within 2 years of infection and sustained viral RNA loads N2000 copies/ml. Slow progressors/controllers had viral RNA loads stable CD4 cell counts above 350 and viral loads b2000
copies/ml in plasma for N3 years.
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time points in the plasma and endocervix did not signiﬁcantly differ
by country (Suppl. Fig. 3a & b). Approximately 8.1% (n = 9) and 7.4%
(n= 13) were classiﬁed as rapid progressors in Uganda and Zimbabwe
(CD4 decline to below 200 cells/mlwithin 2 years of infection) but slow
progressors/controllers (stable CD4 cell counts above 350 and viral
loads b2000 copies/ml in plasma for N3 years post-infection) were ob-
served in b3% (n= 3) of Ugandanwomen versus 10% (n= 18) of Zim-
babwean women (Fig. 2b). It is important to note that when rapid
progressors and controllers were removed from the analyses, the CD4
declines were still signiﬁcantly slower in Zimbabwean versus Ugandan
women (P b 0.001).
3.2. Possible Factors Contributing to Country-Speciﬁc Difference in Disease
Progression
To explain these differences in CD4 T-cell decline in HIV-1 infected
women between countries, we analyzed numerous factors previously
described as correlates of disease progression. Appearance of various
opportunistic infections and secondary infections (malaria, TB, various
STIs) were not signiﬁcantly different in the cohorts and each infection
was treated accordingly upon diagnosis. Other factors such as diet,
recurrent sexually transmitted diseases (chlamydia, trichomonas,
HSV-2, bacterial vaginosis), smoking, sexual behavior, depot-
medroxyprogesterone acetate (DMPA) use, and combined oralcontraceptives (COC) use did not show signiﬁcant differences in HIV-1
disease progression between countries (Morrison et al., 2010;
Morrison et al., 2011; Lemonovich et al., 2015; Lovvorn et al. 2010;
Bark et al., 2010).
There may be a perceived difference in human genetics between
the two countries. Our informed consent and IRB approvals did not
permit genetic testing in these patients. These women self-report-
ed being members of the Shona tribe of Zimbabwe and Buganda
tribe of Uganda. Both are of Bantu origin which has the highest
HLA diversity among humans as well as low frequencies of “HIV
protective alleles”, HLA B57 (3–5%) and B27 (b1%) (Cao et al.,
2004; Paximadis et al., 2012; Kijak et al., 2009) when compare to
Caucasian populations (7.0 and 9.2%, respectively) (www.
allelefrequencies.net/). There are also several reports of the Bantu
(of both Uganda and Zimbabwe) and African populations in general
having low frequencies of CCR5Δ32 deletions. Genome-wide asso-
ciation studies in African ancestry populations did not reveal a sin-
gle genetic polymorphism associated with slow disease progression
and protection from HIV acquisition whereas several polymor-
phisms in the HLA region of chromosome 6 (e.g. HLA B5701) did
appear at sufﬁcient frequency in in European ancestry population
to impact HIV-1 disease (Limou and Zagury, 2013). Thus, genetic
polymorphisms are unlikely to be the only explanation for the
striking differences in CD4 decline in the HIV-infected Ugandan
and Zimbabwean women.
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Based on the pol and env coding regions, theUgandanwomen, all re-
siding in Kampala, were predominantly infected with HIV-1 subtype A
(68%, n = 76) followed by subtype D (28%, n = 31), 3 cases of subtype
C, and 2 intersubtype A/D recombinants (Suppl. Figs. 5 & 6). Previous
studies in Kampala, Uganda involving over 1500 HIV-infected patients
showed a similar frequency of HIV-1 subtype and less than a 5% fre-
quency of intersubtype HIV-1 recombinants (within or between pol
and env genes, roughly three quarters of the genome) (Kyeyune et al.,
2013). With full genome sequencing, intersubtype recombinants are
generally detected at a 5–10% frequency in Kampala, Uganda. Most
HIV-1 recombinants in East Africa are unique recombinant forms that
have recently emerged or have very limited transmission chains with
minimal evidence of extensive spread as observed with circulating re-
combinant forms (CRFs, speciﬁcally 02 and 06) found in the historic or-
igin/epicenter, i.e. the Congo basin and its watershed regions in West
Africa.
All 174 Zimbabwean women were infected with HIV-1 subtype C.
Based on the infecting subtype, womenwith subtype C HIV-1 infections
had CD4 T-cell declines (−0.489 cells/week, GEE model) 2.5-fold and
1.6-fold slower than with subtype D and A infections, respectively
(Fig. 2c). The faster CD4 T-cell declines in subtype D infections also re-
sulted inmore patients (45%, n=14) requiring cART than inwomen in-
fected with subtype A and C (28% and 32%) (Suppl. Fig. 1b). Slow/non-
progression (deﬁned as controllers) was not observed among the sub-
type D infected women as compared to the 4% (n = 3) and 10% in the
subtype A and C infected women, respectively. In contrast, subtype A,Fig. 3. Comparing disease progression in a subset of 56 women in Uganda and Zimbabwe infe
subtype C infected women deﬁned as slow progressors/controllers (a), as typical progressors
progressors (d), and in subtype D infected women deﬁned as typical progressors (e). (f)(g)(h
slow progressors, A typical progressors and D typical progressors, respectively.D, and C infected women had similar frequencies of rapid progressors
(8.5, 11, and 7.5%, respectively) (Fig. 2d). Again, viral levels at set
point (Suppl. Fig. 3c) in plasma or endocervical mucosa or in plasma
during disease (Suppl. Fig. 3 d, e & f) did not differ by subtype (statistical
analyses in Suppl. Fig. 3g).
To illustrate the subtype-speciﬁc differences, CD4 T-cell and viral
RNA levels were plotted for subtype C and A controllers (Fig. 3a & c re-
spectively) and subtype C, A, and D typical progressors (Fig. 3b, d & e re-
spectively) (nine patients for each). The controller status in subtype C
infected patients is quite evident with b0.03 CD4 cells lost per week
(based on all 13 controllers) (Fig. 3a) as compared to the 0.48 lost per
week (linear regression or GEE model) in the 148 typical subtype C
progressors (Fig. 3b). This rate of CD4 T-cell decline in subtype C is
slower than that observed in the typical subtype D (Fig. 2e) and subtype
A (Fig. 3d) progressors (−1.0 and−0.60 CD4 cell loss/week, respec-
tively, linear regression and GEE). Following the set point, viral load in-
creases were similar in all the subtype A, C, and D progressors (Fig. 3g, i,
& j) but viral loads remained the lowest in the subtype C controllers
with an actual decrease over time (−4 HIV-1 RNA copies/ml/week;
Fig. 3f).
3.4. Phenotypic Differences between HIV-1 Subtypes
For this study,we analyzed 185dual HIV-1 competitions in HIV-neg-
ative PBMCs involving 47 subtypes A, D, and C HIV-1 isolates against 25
subtype B isolates (Fig. 4a & b). In these dual infection/competitions, ab-
solute virus production can vary 100-fold in PBMCs of different human
donors but the relative production (i.e. ﬁtness) of one virus versus thected by different subtypes. (a)(b)(c)(d)(e) CD4 cell counts/ml were plotted over time in
(b), in subtype A infected women deﬁned as slow progressors/controllers (c), as typical
)(i)(j) Viral RNA loads in plasma of subtype C slow progressors, C typical progressors, A
Fig. 4.Relative replicative ﬁtness of HIV-1 subtype A, B, C, andD inhumanperipheral bloodmononuclear cells. (a) 12 subtype A, 8 subtypeD, and 27 subtypeCHIV-1 primary isolateswere
competed against 25 subtype B HIV-1 isolates in PHA-activated, IL2-treated PBMCs of HIV-negative donors in series of published and unpublished studies. All competitions in PBMCs
involved the use of 0.001 infectious units of virus to 1 cell. The relative production of two viruses in each competition was measured by a radiolabeled heteroduplex tracking assays or
using next generation sequencing (Abraha et al., 2009; Ball et al., 2003; Arien et al., 2005). Production of individual HIV-1 isolates in a dual infection (f0) divided by its initial
proportion in the inoculum (i0) is referred to as the relative ﬁtness (w = f0/i0). In this study, w is expressed as percent replication of the subtype A, C, or D HIV-1 isolates relative to
subtype B HIV-1. Assay sensitivity is 100-fold differences in replicative ﬁtness. (b) The relative replicative ﬁtness of the subtype B HIV-1 isolates in competition with the subtype A, C,
and D HIV-1 (the reciprocal of a). Symbols with thick outlines represent replicative ﬁtness of the classiﬁed virus at N100-fold or b0.01-fold to competitor virus. The shaded symbols
represent the replicative ﬁtness values of primary HIV-1 isolates. The open/white symbols represent the replicative ﬁtness values of replication-competent chimeric viruses containing
the env gene of a subtype A, C, or D virus within the NL4-3 subtype B backbone. (c) and (d) Replicative ﬁtness of chimeric viruses derived from env gene of 5 subtype A, 3 subtype D,
and 5 subtype C AHI of this cohort. These 13 AHI chimeric viruses were competed against the reference subtype B HIV-1 isolates, B-QO (c) and B-K44 (triplicate).
310 C.M. Venner et al. / EBioMedicine 13 (2016) 305–314other typically varies b10% (Abraha et al., 2009; Ball et al., 2003; Arien et
al., 2005). Subtype CHIV-1 isolates are clearly lessﬁt in PBMCs than sub-
type A and D HIV-1 isolates (P b 0.002) when competing against sub-
type B HIV-1 (Fig. 4a). Subtype C viruses were not detected (i.e. 100-
fold less ﬁt) in 60% (n = 74/123) of the competitions despite the fact
that these same subtype C viruses were readily detected in mono-Fig. 5. Function, cell-to-cell transmission efﬁciency and viral fusion of the Env glycoprotein de
infections in Ugandan and Zimbabwean women was cloned into the pREC-nﬂ HIV-1 genom
receptor usage of the Env glycoprotein from these 14 subtype A, 4 subtype D, and 16 subtype
the 34 Env produced in the context of virus-like particles (VLPs) could mediate cell fusion vi
RLUs) (data below range of graph in (a)). (a) Cell-to-cell fusion between the U87.CD4.CCR5
and the 293T effector cells expressing the 34 Env glycoproteins in context with HIV-1 VLPs
reverse transcription and cannot induce luciferase expression in the target cells. (b) Schemat
was added at 30 min to 10 h post incubation of the effector and target cells. (c) Box plot
glycoproteins expressed in context with the HIV-1 VLPs. (c) Schematic of the viral fusion assa
CCF2 dye in target cells and changes the ﬂuorescent spectrum. (d) Relative entry over time (0
subtype D, and 16 subtype C Env glycoproteins from acute/early infections. (e) Spectral shift c
carrying the CCF2 dye.infections or competitions against other subtype C isolates (Abraha et
al., 2009; Ball et al., 2003; Arien et al., 2005). These competitions suggest
a ﬁtness order of HIV-1 subtype B=D N A N C in human PBMC or prima-
ry CD4 T-cells (Fig. 4) (Abraha et al., 2009; Ball et al., 2003; Arien et al.,
2005). We have previously reported that the replicative ﬁtness of pri-
mary HIV-1 isolates is dominated by the env gene and by the rate ofrived from acute subtype A, C, and D HIV-1 infections. The HIV-1 env gene of acute/early
ic vector by yeast-based recombination/gap repair as described. The function and co-
C acute/early infections was accessed using the Veritrop cell-to-cell fusion assay. None of
a the CXCR4 co-receptor within U87.CD4.CXCR4 cells (below negative control and 1000
target cells expressing Fireﬂy Luciferase upon Tat/Rev-mediate expression from pDM1.1
. The NL4-3 nﬂ VLPs are morphologically identical to wild type HIV but is incapable of
ic of the time-of-drug-addition experiment using the Veritrop assay. 2 μM of Enfuvirtide
of the time to 50% inhibition by Enfuvirtide of cell-to-cell fusion mediated by 34 Env
y which can be monitored by HIV-1 carrying a BlaM-Vpr fusion protein that cleaves the
–600 min) into U87.CD4.CCR5 cells by the chimeric HIV nﬂ carrying the 14 subtype A, 4
urves and box plot of the time required for maximal virus entry into U87.CD4.CCR5 cells
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2005; Ball et al., 2003). Five subtype A, 5 C, and 3 D HIV-1 env genes
(from 13 patients) derived from AHI were used to produce chimeric
virus (subtype B NL4-3 backbone) which were then competed against
the B-QO and B-K44 subtype B reference viruses (Fig. 4c & d, respective-
ly). The AHI subtype D Env chimeric viruses were able to compete with
both the B-Q0 and B-K44 reference viruses whereas the AHI subtype A
Env chimeric viruses were less ﬁt (Fig. 4c & d). In contrast, AHI subtype
C Env chimeric viruses had extremely low replicative ﬁtness or were
completely outcompeted by the B-K44 and B-Q0 reference viruses. To
demonstrate that these differences are due to subtype rather thanwith-
in patient ﬁtness increase, the relative ﬁtness of viral isolates from
chronic infections were compared to isolates from AHI for both individ-
ual subtypes and all isolates (p N 0.05, Suppl. Fig. 4). Thus, lower “path-
ogenic” ﬁtness of subtype C HIV-1 is also observed at initial infection
and may be predictive of slower disease progression.
HIV-1 infection can be mediated by cell-to-cell virus transfer or by
direct virus infection. We examined cell-to-cell infection using the
more physiological Veritrop system (Weber et al., 2013) where trans-
fection of the pREC-nﬂHIV-1 vector into 293T effector cells can produce
HIV-1 particles (non-infectious) and can mediate fusion with the
U87.CD4.CCR5 target cell. Initial assays without Enfuvirtide were used
to validate CCR5 tropism in all patient envelopes (Fig. 5a) In addition,
we only detected Env-mediated cell fusion with U87.CD4.CCR5 target
cells and not with U87.CD4.CXCR4 cells. Absolute level of cell-to-cell
HIV transmission was similar with 34 AHI env genes in pREC-nﬂ over
a 12 h incubation (Fig. 5a). Cell-to-cell fusion kinetics was then mea-
sured using a time-of-drug-addition experiment where Enfuvirtide, an
inhibitor of HIV-1 entry,was added at different times post co-incubation
of effector + target cells (Fig. 5b). AHI subtype C HIV-1 Env glycopro-
teins mediated signiﬁcantly slower rates of cell-to-cell HIV-1 infection
than did AHI subtype A (P b 0.001) or subtype D (P b 0.001) Env glyco-
proteins based on the T1/2 of Enfuvirtide inhibition (Fig. 5c).
Finally, the rate of free virus entry into host cells (U87.CD4.CCR5)
wasmeasuredusing these same 34AHIHIV-1. In thisMiller et al. system
(Lineberger et al., 2002), pREC-nﬂ was co-transfected with pMM310
BlaM-Vpr to produce HIV-1 particles harboring a Vpr-BlaM fusion pro-
tein (Fig. 5d). Upon de novo infection, the HIV_nﬂ is fully capable of
host cell entrywhich releases theVpr-Beta-lactamase to cleave theﬂuo-
rescent CCF2dye and changeﬂuorescent spectra (Fig. 5d) (Lineberger et
al., 2002). The rate of virus entry into host cells was the slowestwith the
16HIV_nﬂ harboring the AHI subtype C envelopes as compared to those
carrying the AHI subtype A (P b 0.05) and subtype D envelopes
(P b 0.001) (Fig. 5e & f).
4. Discussion
By the 1980s, all the HIV-1 subtypes had emerged, were circulating
and recombining in the Congo basin aswell as spreading to neighboring
countries/regions (Tebit and Arts, 2011). Various HIV-1 subtypes were
introduced in multiple geographic regions (South Africa, Zimbabwe,
Brazil, India, etc) (Arien et al., 2007) by the late 1990s and yet, subtype
C HIV-1 rose in prevalence faster than any other subtype in the hetero-
sexual population (b10% in early 1990s to N50% today) (Arien et al.,
2007) (Fig. 1). We have previously reported that HIV-1 subtype C iso-
lates had lower replicative ﬁtness in human T-cells and macrophages
than other group M subtypes (Abraha et al., 2009; Ball et al., 2003;
Arien et al., 2005) but could only speculate that HIV-1 subtype C may
cause slower disease progression (Arien et al., 2007). Aside from regions
in Brazil, Tanzania, and Kenya, HIV-1 subtype C typically dominates in
regional pandemics and does not co-circulate at high frequencies with
other HIV-1 subtypes in human populations (Arien et al., 2007). As a
consequence, comparing disease progression related to different HIV-1
subtype infections in a single country or region is very difﬁcult. Thus,
we screened for and recruited 300 AHI in Ugandan and Zimbabwean
women and then followed the natural history of these HIV infectionsfor 5–9 years in the absence of treatment. With this cohort in Uganda
and Zimbabwe, we have a population of only women, all of Bantu
origin, all recruited within AHI (following heterosexual transmission),
and ﬁnally, representing the subtype A, C and D HIV cohorts for sufﬁ-
cient statistical power tomeasure differences in disease progression. In-
dependent statisticians at two different institutions (FHI 360 and Case
Western Reserve University) analyzed the cohort data presented here-
in. The 2-fold difference in disease progression between these two
countries was not attributable to diet, secondary/opportunistic infec-
tions, sexual habits, or age (Lemonovich et al., 2015). Of course, we
could not screen for presence or absence of all pathogens,
sociodemographic or tribal/population differences but the question-
naires administered by medical ofﬁcers at each patient visit was exten-
sive as was the tests for various clinical chemistries and other health
indicators. Examples of the questionnaire and acquired laboratory
data is available upon request. We are currently interest in screening
themicrobiota in the vaginal tract of thesewomen to assess possible dif-
ferencewhichmay be associatedwith disease progression but again,we
do anticipate differences that segregate by country given the similar diet
and diverse human genetics. Of all the parameters tested, only HIV-1
subtypes could clearly delineate differences in the rate of CD4 cell de-
cline in blood. Infectionwith subtypeCHIV-1 resulted in the slowest de-
clines in CD4 T-cell counts (0.489 cells/week) as compared to subtype A
(0.781 cells/week) and then subtype D HIV-1 infection with the most
rapid declines in CD4 T-cell counts (1.231 cells/week).
Like other natural history cohorts, rapid disease progressionwas ob-
served at a 7–9% frequency regardless of HIV-1 subtype but slow
progressors/controllers appeared only in subtype A and C infections.
The differential rates of CD4 T-cell declines (D N A N C) was still signiﬁ-
cant when rapid progressors and controllers were removed from the
analyses. We have proposed that a combination of “good” host genetics
(e.g. HLA B27 or B57) and infection with HIV of low replicative ﬁtness
may result in “elite” HIV control (Lobritz et al., 2011), i.e. a rare condi-
tion in Africa but closely approximated by the 13 subtype C infections
with no declines in CD4 cell counts and b103 copies/ml of virus for N
5 years of infection (Fig. 3a & f).
Based on previous human genetic studies across Africa (Cao et al.,
2004; Paximadis et al., 2012; Kijak et al., 2009; McLaren and Fellay,
2015; McLaren and Carrington, 2015) (www.allelefrequencies.net/),
we now know that the Bantu population has the greatest genetic diver-
sity of Homo sapiens. Low prevalence of “HIV protective” polymor-
phisms/alleles in the Shona and Buganda tribes (both Bantu) (e.g. b5%
of CCR5Δ32, CCR2a 64I, HLA-B57 and B27) could not explain the dra-
matic differences in disease progression. Interestingly, there were no
signiﬁcant differences between countries or HIV-1 subtypes in the
viral RNA levels at set point or over the course of infection. In our previ-
ous report using 188 patients for this cohort and withminimal analyses
of follow up (b3 years), we observed a slightly higher viral loads at set
point in subtype C and D versus A infections (p b 0.04, ANOVA) that
has not held signiﬁcance when expanding to the 286 patients in this
study (Morrison et al., 2010). Instead, expansion of the cohort size
now showed a trend for lower viral load set points in subtype C infec-
tions versus A or D (Suppl Fig. 3c). Regardless, it is again important to
stress that we did not observe any signiﬁcant differences in viral load
during disease based on infection by speciﬁc HIV-1 subtype.
Most studies examining disease progression in natural history co-
horts are now impossible and unethical based on WHO guidelines for
the initiation of cART in all HIV positive patients regardless of CD4 T-
cells counts (http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/
en/). With the start of this study in 2000, we followed WHO/UNAIDS
guidelines to treat with CD4 cell counts ≤200/ml which was controver-
sial because few charities, governments, and international organizations
(e.g. WHO, PEPFAR) had rolled out their treatment programs in Africa.
During this ten year cohort study, 33% of the participants received treat-
ment at an average of 1500 days post-infection. Subtype D infected
women were ~1.7-fold more likely to receive treatment than subtype
313C.M. Venner et al. / EBioMedicine 13 (2016) 305–314A or C infected women. By modelling the rates of CD4 declines in this
natural history cohort, the projected time to reach ≤200/ml or AIDS in
these women was 1.3 fold longer with subtype C (estimated mean of
12.3 years) than A (9.5 years) and 2.0 fold longer with C than subtype
D (6.2 years). Historical data of subtype B infections in North America
and Europe suggest 6–8 years as an approximate time to reach AIDS
(CD4 T-cells b200/ml) (Munoz et al., 1995; Mellors et al., 1996) but
there are no natural history cohorts from diagnosis (prior to treatment)
to establish accurate estimates. Interestingly, despite (i) different geo-
graphical regions, (ii) different human populations, and (iii) higher
rates of parasitic and other co-morbities in Uganda, infectionswith sub-
type B in North America and D in Ugandamay have similar rates of CD4
T-cell declines and time to AIDS. Subtype B and D HIV-1 share the most
sequence homology of all subtypes and several studies suggest that sub-
type Bwas a sub-branch and “member” of subtype D super-cluster. Ear-
lier reports have also described faster disease progression and reduced
response to treatment in East Africans infected with HIV-1 subtype D
than subtype A (Baeten et al., 2007; Kaleebu et al., 2002; Kyeyune et
al., 2013).
HIV-1 subtype C isolates are less ﬁt than subtype A which are both
less ﬁt than subtype B and D HIV-1 isolates, a ﬁnding established by
over 2000 direct head-to-head dual virus competitions in primary
CD4+ T-cells and macrophages from HIV-negative donors of different
races/ethnicities (Abraha et al., 2009; Ball et al., 2003; Arien et al.,
2005). These ﬁndings suggest a direct association between the replica-
tive ﬁtness of HIV-1 and subsequent disease progression. In addition,
the HIV-1 env genes derived from 47 women with AHI also showed
that subtype C as compared to subtype A and D were slower in host
cell entry by free virus and slower in cell-to-cell transfer of virus. Previ-
ous reports have also demonstrated that subtype C viruses rarely switch
to a CXCR4 using or dual co-receptor using phenotypewhereas subtype
D HIV-1 shows higher percentage in switching to CXCR4 co-receptor
usage during disease as compare to patients infected with subtype A
HIV-1 (or HIV-1C). More rapid progression in subtype D infected pa-
tientsmay be associatedwith themore common switch to CXCR4 tropic
virus but again, this appears to be an inherent attribute of the viral sub-
type and not due to host genetics. HIV-1 subtype B found in North
America and Europe is closely related to subtype D found in East Africa
and both B and D have similar propensities to switch to a CXCR4 using
phenotype late in disease progression. Overall, these observations sug-
gest that infecting HIV-1 subtype may actually set the course of subse-
quent disease progression.
In summary, this largest natural history cohort of non-subtype B in-
fected women revealed a signiﬁcant difference in HIV-1 subtype viru-
lence with ramiﬁcations for HIV-1 spread and treatment in the global
epidemic. Women infected with HIV-1 subtype C progressed to AIDS
at least 1.5-fold slower than women infected with subtype A or D. Lon-
ger asymptomatic periods with subtype C infections (between 3 and
5 years longer) will lead to greater probability of transmission, especial-
ly among those discordant couples with unknown infection status
(http://www.who.int/hiv/pub/progressreports/update2014/en/).
Using human cervical and penile explant tissues, transmission “ﬁtness”
appears to be similar among most HIV-1 subtypes (Abraha et al., 2009;
King et al., 2013). Thus, the expansion of HIV-1 subtype C infections in
the global epidemic may be related to the low virulence of subtype C,
resulting in long periods of asymptomatic periods, and leading to in-
creased opportunity for heterosexual transmission over other HIV-1
subtypes. Ultimately, HIV-1 subtype C may be more “ﬁt” in the human
population based on low subtype virulence and high transmission
efﬁciency.
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